Antares Pharma, Inc. (NASDAQ:ATRS) reached a new 52-week high during trading on Monday . The company traded as high as $3.42 and last traded at $3.43, with a volume of 3,302,437 shares traded. The stock had previously closed at $3.24.

A number of research firms recently weighed in on ATRS. Chardan Capital started coverage on Antares Pharma in a report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Antares Pharma in a research note on Sunday, September 10th. Vetr raised Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 price objective on the stock in a research note on Tuesday, July 18th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Antares Pharma in a report on Friday, September 8th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $4.34.

The firm’s 50 day moving average is $3.04 and its 200-day moving average is $2.91. The company’s market capitalization is $534.91 million.

Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.42 million during the quarter, compared to the consensus estimate of $12.99 million. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. On average, equities analysts forecast that Antares Pharma, Inc. will post ($0.11) earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. National Planning Corp boosted its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares in the last quarter. KCG Holdings Inc. grew its stake in shares of Antares Pharma by 48.8% during the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 21,881 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Antares Pharma by 10.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company’s stock worth $822,000 after buying an additional 26,847 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Antares Pharma by 20.1% during the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock worth $476,000 after buying an additional 28,029 shares during the last quarter. Finally, MML Investors Services LLC grew its stake in shares of Antares Pharma by 228.2% during the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 30,000 shares during the last quarter. 36.77% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Antares Pharma, Inc. (ATRS) Reaches New 12-Month High at $3.42” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/02/antares-pharma-inc-atrs-reaches-new-12-month-high-at-3-42.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.